Protocol Ledger

NCT03301597 · Phase II · TERMINATED

NLA101 in Adults Receiving High Dose Chemotherapy for AML

Interventional Phase II clinical trial protocol NCT03301597 sponsored by Nohla Therapeutics in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2018-01-24 Enrollment: 146 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT03301597
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)146 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT03301597
Protocol FieldVerified Registry Value
NCT IdentifierNCT03301597
Consolidated Lead SponsorNohla Therapeutics
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusTERMINATED
Registered Enrollment146 participants (ACTUAL)
Registered Start Date2018-01-24
WhyStopped ClassificationUnspecified

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI